

# CONSOLIDATE. ACCELERATE.

### Index

About Us Corporate Identity Our presence	2
Strategic Leadership Key performance indicators Chairman's message Managing Director's message	6 8 10
Business Enablers Operating environment Formulations API New acquisition Formulations R&D	12 14 16 18
People and Planet Sustainability Social responsibility Life at SeQuent Board of Directors Leadership team	20 22 24 26 29
Statutory Reports  Management Discussion and Analysis Business Responsibility Report Board's Report Corporate Governance Report	30 43 54 82
Financial Statements Consolidated Standalone Notice	100 178 246
HOLICE	40

#### **Financial Performance**

₹1,094 Mn

Operating EBITDA

7.7% Operating

EBITDA margin

₹4.314 Mn

₹574 Mn

from operations

Cashflow

**(** 5.5%

Revenue from APIs

₹14,128 Mn

Revenue from operations

**1** 3.8%\*

₹9,814 Mn

Revenue from Formulations

**1** 8.4%

₹413 Mn Profit After Tax#

\_\_\_\_

1 Y-o-Y growth over FY21
1 Y-o-Y decline over FY21

\*7.2% in constant currency
# PAT after minority interest

# FY22 highlights

#### **Welcome to SeQuent**

In a short period of time, SeQuent has evolved as the leading animal health company from India, carving out a niche for itself across the world with its unique business model. Sequent has grown from strength to strength, acquiring businesses in key global animal health markets, integrating the entities, scaling operations, and subsequently consolidating them successfully.

Under Sequent 2.0, the Company has put into motion several initiatives, with a strong emphasis on strategic investments to scale and build capabilities. We are exploring new markets, expanding our portfolio, for both Formulations and APIs, entering new segments, and collaborating closely with our valued customers.

Despite increasing uncertainties in the global markets, we are confident in our ability to accelerate competitive growth and achieve the bold ambitions set out in the Sequent 2.0 roadmap. Our diversified market reach, long standing partnerships, consistent focus on innovation, and our deep domain expertise in animal health will contribute immensely towards establishing Sequent as a global animal health major in the coming years.

### Operational

#### API

- Contribution from regulated markets increased from ~ half to 2/3rd of overall API business in the year
- Submitted 1 new VMF filing

   Total 24 USVMF filings and
   11 CEP approvals with 30+
   commercialised APIs offered to
   customers globally
- Mahad site successfully completed the certification audit from TÜV NORD CERT GmbH for ISO 14001 on Environment and ISO 45001 on Health & Safety

- Successfully completed multiple customer EHS audits and external safety audits through Licensed Auditors for our manufacturing sites in India
- Commissioned a pilot plant at Vizag to further augment capabilities
- Capacity ramped up at Indian manufacturing sites to keep pace with increasing demand

Continue to engage with Top 10 animal health companies for sustainable long-term business

#### **Formulations**


- India formulation business crossed landmark of ₹1 Billion in revenues for the year
- Our Turkish facility received EU GMP approval for Tablets line, along with EU GMP renewal for other dosage forms for existing site, to leverage site as base for exports to Europe and othe international markets
- Onboarded sectoral experts to support new growth initiatives and strengthen partnerships with large animal health companies globally

- Consolidated minority stake in Brazil, which is now fully owned, building on the strong track record of successfully Acquiring, Consolidating and Accelerating global businesses
  - Expanded Tulathromycin franchise our first formulation from Indian R&E facility, with launches in multiple markets of Europe and submission of filings in key regulated markets and estrategic emerging markets
- Acquired 100% stake in Nourrie Saúde e Nutrição Animal Ltda (Nourrie) in Brazil, marking entry into the companion animal market, and the 4th largest pet market globally
- Accelerated investments to strengthen our capabilities in manufacturing and compliance, resumed upgrading sterile injectables facility at Bremer in German for US FDA readiness

#### **Corporate identity**

# **CONTINUING OUR LEGACY IN** HEALTHCARE

SeQuent Scientific Limited is India's largest animal health company offering a comprehensive portfolio of Active Pharmaceutical Ingredients (API), finished drug formulations and analytical services, addressing the needs of the animal health sector worldwide. We are also amongst the 'Top 20' in our sector globally, with nine manufacturing facilities across Europe, Turkey, Brazil and India. With The Carlyle Group as our Promoter, we are well supported to explore and pursue new avenues of growth, and the team's efforts are further guided by the valuable experience of our well diversified Board. Sequent offers APIs and finished drug formulations under the brand name Alivira across all global markets while Sequent Research is a contract research organisation with expertise in analytical and bioanalytical services for pharmaceutical, personal care, nutraceutical, and API firms.



Largest Animal health

company from India

9

Revenue from regulated markets

Commercial APIs

**80+** Countries

Manufacturing facilities\*

CSR spend

R&D centres

**1,900+** Employees

Finished dosage formulations across 12 dosage forms

(2 facilities - Campinas and Minas Gerais)]

Collaboration

• Any situation, anytime.

• We adjust to new tasks and

always appear flexible.

Values

Adaptability

- We is stronger than me.
- We encourage everyone to work together believing that the whole is greater than the sum of parts.

#### **Accountability**

• Speak up. Step up.

• Better each day.

cost efficiency.

• We acknowledge and take responsibility for our actions and decisions.

**Continuous Improvement** 

• We improve systems and

procedures for better quality and

#### Integrity

- Do the right thing. Always.
- We respect one another and act honestly at all times.

\*3 in API (Vizag, Mahad, Tarapur), 6 in Formulations [(Ambernath, India), Spain, Germany, Turkey, Brazil

About Us

# **ACHIEVING OPTIMAL SCALE**

. . . . . . . . . . .

. . . . . . . . . . . . . . . .

. . .

0 0 0 0

. . . .

🔾 🗘 Barcelona, Spain

nutritional

premixes

Capabilities: Dedicated

Dosage: Oral solutions/

Approvals: EUGMP

suspensions, powders and

OMinas Gerais, Brazil

Approvals: MAPA

solutions

Dosage: Premixes, tablets,

pastes, suspensions and

beta-lactam powder block &

We have a diversified global presence with manufacturing capabilities across multiple regions including Europe, India, emerging markets such as Latin America, Turkey, and other emerging markets. With 3 API facilities in India, 6 formulation manufacturing facilities and 5 R&D centres globally, we continue to expand and invest in building capabilities in R&D and manufacturing.

. . . . . .

. . . . . .

. . . . . .

00000

. . . . . . . .

. . . . . . . . . .

. . . . . . . . . . . . .

. . . . . . . . . . . . . . .

• • • • • • • •

. . . . . . .

. . . . . . . .

. . . . . . . . . . . . .

00000

. . . . .

0 0 0 0

 $\bullet$ 

 $\bullet \bullet \bullet$ 


 $\bullet$ 

0 0 0

0 0

• • • • • • • • • •

. . . . . . . . .



**♥♥**Campinas, Brazil

Approvals: MAPA

Dosage: Powders and premixes


**Key performance indicators** 

# DRIVING EFFICIENCIES FORWARD


Traversing through the many challenges of FY22, we have grown stronger, and are making good headway with our strategic goals. We are confident about the underlying strength of our organisation to continue delivering exceptional outcomes.








#### Revenue by Markets (Formulations)



#### Revenue by markets (APIs)







- \* PAT after minority interest
- ^ Post demerger of human business

Return on capital employed	(%)	Net debt to equity		Net debt to EBITDA	
FY22	9.80	FY22	0.37	FY22	2.32
FY21	20.20	FY21	0.22	FY21	0.75
FY20	15.60	FY20	0.33	FY20	1.30
FY19	11.70	FY19	0.36	FY19	1.90
FY18	7.80	FY18	0.38	FY18	2.80

Chairman's message

# BANKING ON OUR CAPABILITIES

It gives me immense pleasure to connect with you all again.

While the world started recovering from the pandemic, and economic activity revived in many sectors, new geo-political events threatened to interrupt the return to normalcy. The disruption in supply chains, volatility in prices of input materials and increasing costs of utilities have presented new challenges to all businesses. As your company operates in multiple geographies across the world, we too were not insulated from the impact of the pandemic and these recent developments.

I am proud of the entire SeQuent team for their unstinting efforts, which have helped us to navigate these challenges, as we continue with our endeavour to build a global animal health major from India. The last two years have taught us to be resilient, find innovative solutions, and reinvent ourselves to emerge stronger. The efforts are already evident through the new milestones achieved in all our business.

We are excited by the opportunities that lie ahead of us. The global animal health market was valued at ~US\$ 53 Billion in 2021 and is expected to witness a CAGR of 5% - 7% during this decade. Your company has built a strong foothold and consolidated its position in many key animal healthcare markets, including India, which will provide the springboard needed to accelerate our growth agenda.

Your company with its global presence has already established

itself as a manufacturer of high quality Active Pharmaceutical Ingredients (API) and Formulations, serving customers in the United States, Europe, India, Latin America, and other emerging markets. We are building a strong operational infrastructure with 5 R&D centres, 9 manufacturing facilities across the world, and marketing presence in nearly 80 countries.

Coming to sustainability, we believe that what is good for the society, is good for our business. We are committed to leveraging new technology platforms and using novel approaches, resulting in minimal utilisation of energy resources and better waste management.

During the year our employees were provided free of cost vaccination against Covid-19, as we continued to put the highest priority on the safety and well-being of our employees. I would like to express my gratitude to our people and their families for stretching beyond the normal call of duty and ensuring that we have uninterrupted supply of products for our customers.

Our ambitious plans have been laid out under the Sequent 2.0 strategy.

We have now consolidated our operations substantially and put in place the building blocks needed to accelerate our growth. We are also prepared to face any volatility and have developed agile mechanisms to seize new opportunities for growth and contain costs, while working within the broader framework of our strategy.

We are delighted to welcome Rajaram Narayanan as Managing Director and CEO of the Company. He joins us with a strong track record and experience of leading and transforming businesses in complex and competitive industries. The Board looks forward to partnering with him in the company's next phase of successful growth.

I would like to take this opportunity to thank my fellow Board Members and all the other stakeholders for their valuable guidance, trust, and support towards our vision of creating a global animal healthcare leader out of India.

Warm regards,

**Dr. Kamal K Sharma** Chairman **Managing Director's message** 

# DRIVING GROWTH THROUGH COALESCENCE

I am happy to write to you for the first time as the Managing Director of your Company. Sequent is a unique company, which has systematically built a strong presence across the world in a relatively short period of time.

inform you that even in the face of adversity and a year full of challenges, your company continued to achieve new milestones in line with its strategy.

We are the largest animal health company from India and are currently amongst the Top 20 animal health companies in the world. Our Sequent 2.0 strategy guides our ambition to take big and bold steps to climb up the pecking order and establish ourselves firmly within the upper tier of the industry.

I am proud to inform you that even in the face of adversity and a year full of challenges, your company continued to achieve new milestones in line with its strategy.

We now have a presence across 80 countries. Our recent focus has been to consolidate our businesses across the world. We have made strategic acquisitions over the last few years across regulated markets, which are at the forefront of the animal healthcare industry. The formulations business, which is a major driver of your company's growth, registered two-thirds of its revenues from regulated markets. Our regional presence and world class manufacturing capabilities have helped us to exploit the opportunities available in these markets.

Brazil is the 4<sup>th</sup> largest animal health market in the world. Since its acquisition in 2016, Alivira Brazil has emerged to be amongst the Top 10 animal health players in Brazil, having grown significantly at a CAGR of 57% over the last 5 years. We have taken a step further this year and acquired 100% stake in Nourrie, which came with a portfolio of 23 commercialised products, and a near-term pipeline of 17 products for pet and swine

categories. With the consolidation of Alivira's business in Brazil, we now have full ownership in most of our subsidiaries. This will enable us to leverage the unique capabilities in our markets, create synergies and accelerate growth.

Our formulations business grew at a CAGR of 11% over the last 4 years, clocking a revenue of ₹9.8 Billion in this financial year. The formulations business in India crossed the landmark of ₹1 Billion in annual revenues. Post the relaxation of pandemic related restrictions, we have also resumed the upgradation of our formulations facility in Germany, to serve the markets in Europe and USA

Your company also has the distinction of being the only one in India to have established a USFDA approved greenfield dedicated veterinary API facility. We successfully completed several customer audits at this facility. The manufacturing facility at Mahad also successfully completed the audit certification from TÜV NORD CERT GmbH for ISO 14001 on Environment and ISO 45001 on Health & Safety. The API business achieved revenues of ₹1.4 Billion in Q4 FY22, achieving the highest ever quarterly performance, and closed the year with ₹4.3 Billion in total revenues for FY22. Your company also successfully commercialised 1 new API and submitted a new US VMF filing, taking the total of commercialised APIs up to 31.

In aggregate, we reported a revenue of ₹14.1 Billion, which saw a 3.8% growth (7.2% in constant currency

terms). Macroeconomic factors and currency volatility, especially in Turkey, had a bearing on our financials. The Turkish Lira moved from 8.33 to a US\$ in March 2021 to 14.65 to a US\$ in March 2022. This unfavourable currency depreciation caused a reduction in net worth by about ₹797 Million. However, we have a leading position in the Turkish market, which is gaining strength on the back of our local manufacturing capabilities and strong branded generics business.

Our concerted efforts towards building strong partnerships, and continued investments in building capabilities in R&D and manufacturing, will provide a strong pipeline of products.


I thank our Board for their valuable quidance and all our stakeholders for supporting us in our journey. I am truly proud of the work that has been put in over the past few years, to bring the company to an enviable position. It is an honour to lead the team at Sequent through this exciting next phase of growth towards building a significant and large global animal health company from India.

Warm regards,

Rajaram Narayanan Managing Director

#### Operating environment

# TRENDS SHAPING OUR STRATEGY



#### Pet animals

Demand for pet ownership is increasing in recent times considering the evolving social fabric, greater nuclearisation of families and the desire for companionship with pets post the lockdown era. Pets are recognised as not just companions but play an important role in improving people's mental health and wellbeing. The perspective has changed from pet ownership to responsible pet parenthood. This rise in companion animal ownership has given an impetus to the demand for pet healthcare, as pet parents and caregivers value them just like their family members. The global pet pharmaceuticals sector is expected to drive growth for the overall animal healthcare sector in the near future.





#### Prevalence of xoonotic diseases

The wellbeing of human beings and the environment at large is intrinsically connected with the health of animals, be it livestock or pets. There is an increasing threat of viruses and bacteria passing from infected animals and crossing the species barrier to affect human beings, leading to pandemic situations. This increased incidence of zoonotic diseases is a key contributing factor in the growing demand for animal health products and services. Increased adoption of healthcare products to prevent diseases, focus on general well-being and meeting nutritional requirements of the animals, in addition to treating them for any illnesses, is further driving growth in the sector.

#### Market size estimation 2021 (US\$ Billion)

15.5 North America Europe

5.5 LATAM

Emerging markets

Source: Research Reports, Internal Estimates

https://www.globenewswire.com/newsrelease/2022/04/13/2422121/0/en/Animal-Healthcare-Market-Size-to-Hit-US-76-82-Billion-by-2030.html

https://www.marketdataforecast.com/ market-reports/la-veterinary-healthcare-

https://www.marketdataforecast.com/ market-reports/eu-veterinary-healthcare-

#### **Formulations**

# **GROWTH ACCELERATOR**

Our formulations business continues to grow, contributing to 69% of total revenues globally. LATAM and India markets delivered market beating growths. Our industry insights allow us to create a tailored portfolio of potent and diversified products that cater to the needs of animal species we serve. Our product range includes nutrition, pain management, anthelmintics, antibiotics, and gut health management products, to name a few.

# Consolidation

Minority stake in Brazil business making Brazil entity fully owned by Sequent

## Acceleration

100% stake in Nourrie Saúde e Nutrição Animal Ltda ('Nourrie') in Brazil



# Key highlights

#### Tulathromycin launch

In FY21, we launched Tulathromycin, our first inhouse developed injectable in Europe. FY22 was the first full year of commercialisation, and we are delighted to share that the product performed above our expectations.

#### **Acquisitions**

In February 2022 we acquired 100% stake in Nourrie Saúde e Nutrição Animal Ltda ('Nourrie') in Brazil, marking Alivira's entry into the fast-growing pet segment in Brazil, the 4<sup>th</sup> largest companion animal market in the world.

#### Growth drivers

### ∇ Strategic investments

We have initiated work on the capability and capacity expansion of our injectable facility in Bremer, Germany, for USFDA Approval and US commercialisation, which has been delayed due to COVID-19 related travel restrictions in Europe, delaying the facility upgradation work.

# Strengthening presence and expanding portfolio

The conclusion of Nourrie's acquisition marks an important milestone in the SeQuent 2.0 strategy of establishing our presence in Brazil's pet market, the fastest growing segment. Brazil is the 4<sup>th</sup> largest pet market in the world, with an estimated market size of R\$ 1.8 Billion, growing annually at ~16%. The addition of Nourrie has nearly doubled the product portfolio available to Alivira for commercialisation in Brazil, with additions in both the nutraceutical and therapeutic product categories. Nourrie also brings a strong pipeline of 20 products under development, 12 of which are planned for launch in the next fiscal. Brazil has emerged as our third largest market, next only to Spain and Turkey.



1,000+
Formulations



80+
Countries



~2/3<sup>rd</sup>
Sales to regulated markets



25+
Products under development



6
Manufacturing facilities




4 R&D centres **API** 

# A STRONG PILLAR POWERING OUR CAPABILITIES

Global animal health companies rely and trust us for our ability to deliver quality APIs. Our API facilities have a strong track record of regulatory compliance, ensuring high quality standards and service commitments that help our customers to sustain their market share.

### Key highlights

Particulars	FY22 Updates/ Developments	Total Products
Commercialised	1	31
US VMF Filing	1	24
<b>EU CEP Approvals</b>	-	11



#### Growth drivers

## 

With rising input material costs, a systematic cost reduction programme has been rolled out for our top products to enhance our cost competitiveness in price sensitive emerging markets. We achieved significant cost reductions for one of our top molecules, and also simplified our supply chain significantly. This cost reduction programme will continue in the next year, with enhanced focus, higher resource allocation and augmented infrastructure.

## Strengthening partnerships with the large global Animal Health companies

We are now seen as a strategic supplier by Top Animal Health players, having developed commercial relationships with most of them. We also established an advisory committee, with the aim of garnering higher wallet share.

### ∇ Portfolio diversification

We have been successful in broad-basing our portfolio, leading to the diversification of our revenue base across different products.

### 

We commissioned the  $7^{th}$  clean room in Vizag, enhancing our capacity by ~20%.

### 

We expect to drive benefits from the agreements signed with 2 Top-10 animal health companies, some of which will commence in the later part of FY23. We continue to strategically engage with top animal health companies as part of our long-term strategy.



**24**US VMF filings



**11**CEP approvals



~3/4<sup>th</sup>
Sales to regulated markets



8+
Products pipeline



Manufacturing locations



R&D centre